{"entity": "researcher", "timestamp": "2026-09-23T21:55:44.196Z", "family": "Damkier", "given": "P", "initials": "P", "orcid": "0000-0003-0591-7187", "affiliations": ["Department of Clinical Chemistry & Pharmacology, Odense University Hospital, Odense, Denmark.", "Department of Clinical Research, University of Southern Denmark, Odense, Denmark."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/3220b6c562f2497f9122594f270ba2ab.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/3220b6c562f2497f9122594f270ba2ab"}}, "publications": [{"entity": "publication", "iuid": "d413d5d0e7b84b61a960fa93b787591a", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/d413d5d0e7b84b61a960fa93b787591a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/d413d5d0e7b84b61a960fa93b787591a"}}, "title": "Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia.", "authors": [{"family": "Cesta", "given": "Carolyn E", "initials": "CE", "orcid": "0000-0001-5759-9366", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/35e1b896082549c2b69ead371bf4e3a8.json"}}, {"family": "Segovia Chac\u00f3n", "given": "Silvia", "initials": "S", "orcid": "0000-0003-0210-5829", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2e63ae649a0e4a18847b5e19d73ea48b.json"}}, {"family": "Engeland", "given": "Anders", "initials": "A", "orcid": "0000-0001-5620-9207", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fa92583833b8407392fef0584366c87e.json"}}, {"family": "Broe", "given": "Anne", "initials": "A", "orcid": "0000-0002-4149-8808", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9ff2659b76694a548fb6a84225f90885.json"}}, {"family": "Damkier", "given": "Per", "initials": "P", "orcid": "0000-0003-0591-7187", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3220b6c562f2497f9122594f270ba2ab.json"}}, {"family": "Furu", "given": "Kari", "initials": "K", "orcid": "0000-0003-2245-0179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f00c9192b2a642869c13e93ca5526147.json"}}, {"family": "Kieler", "given": "Helle", "initials": "H", "orcid": "0000-0001-9338-7133", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/831da95a6b2f4a9b9e29aed574219101.json"}}, {"family": "Karlsson", "given": "P\u00e4r", "initials": "P", "orcid": "0000-0002-7177-1713", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9177884596f74f758d9a3cbfc472a8e0.json"}}], "type": "journal article", "published": "2021-11-00", "journal": {"title": "Acta Obstet Gynecol Scand", "issn": "1600-0412", "volume": "100", "issue": "11", "pages": "2111-2118", "issn-l": null}, "abstract": "For phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, the only approved indication in women is for pulmonary arterial hypertension. These drugs are increasingly being proposed and tested for treatment of female infertility and complications in pregnancy. However, the extent of use of PDE5 inhibitors in the general pregnant population over the last decades is unknown. Therefore, we conducted a descriptive cohort study using data from the population health registers in the Scandinavian countries.\n\nBy linking the Medical Birth Registers and the Prescribed Drug Registers in Denmark (1997-2017), Norway (2004-2017), and Sweden (2006-2016), women with filled prescriptions of PDE5 inhibitors in outpatient settings in the 90 days before the date of last menstrual period and/or during pregnancies were identified. With additional linkage to the National Patient Registers, information on maternal, pregnancy, and infant characteristics, co-morbidities, and co-medication was collected and described.\n\nAmong over 3 million singleton pregnancies, only 77 were pregnancies in women who had at least one filled prescription of a PDE5 inhibitor within the 90 days before the start of pregnancy to delivery. Prescription fills most often occurred before the last menstrual period and in the first trimester, with very few occurring later in pregnancy. Sildenafil was the most used PDE5 inhibitor. Among pregnant women using PDE5 inhibitors, 44% were 35 years of age or older, eight had a cardiovascular diagnosis, and three specifically had a diagnosis of pulmonary arterial hypertension. Among the infants born to mothers using PDE5 inhibitors, nine were born preterm, six were small-for-gestational age, five had an Apgar score at 5 minutes below 8, 18 were admitted to the Neonatal Intensive Care Unit, and eight had respiratory and cardiovascular conditions.\n\nFew women used PDE5 inhibitors in outpatient settings before or during pregnancy in the Scandinavian countries in the last decades. Only a small proportion had a diagnosis for pulmonary arterial hypertension, suggesting off-label use in the remaining users. Use was predominantly in mothers over age 35 years. The safety of fetal exposure to sildenafil and other PDE5 inhibitors in pregnancy has not been established. As maternal age continues to increase and additional uses of PDE5 inhibitors are investigated, the safety of these drugs in pregnancy should be thoroughly evaluated.", "doi": "10.1111/aogs.14251", "pmid": "34453753", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T13:11:17.932Z", "modified": "2026-09-23T13:11:18.147Z"}, {"entity": "publication", "iuid": "7082e012404d45b18ee84d3636cd7299", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/7082e012404d45b18ee84d3636cd7299.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/7082e012404d45b18ee84d3636cd7299"}}, "title": "Use of hypnotic drugs among children, adolescents, and young adults in Scandinavia.", "authors": [{"family": "Wesselhoeft", "given": "Rikke", "initials": "R", "orcid": "0000-0001-9700-2739", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/29670ecb185844689260deb334d8ef10.json"}}, {"family": "Rasmussen", "given": "Lotte", "initials": "L"}, {"family": "Jensen", "given": "Peter Bj\u00f8dstrup", "initials": "PB"}, {"family": "Jennum", "given": "Poul J\u00f8rgen", "initials": "PJ", "orcid": "0000-0001-6986-5254", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/01b009348f0846beb1d0c60941b1ca28.json"}}, {"family": "Skurtveit", "given": "Svetlana", "initials": "S"}, {"family": "Hartz", "given": "Ingeborg", "initials": "I"}, {"family": "Reutfors", "given": "Johan", "initials": "J", "orcid": "0000-0003-1372-4262", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/dbc162955acf4b2ba0b4dade363d4592.json"}}, {"family": "Damkier", "given": "Per", "initials": "P", "orcid": "0000-0003-0591-7187", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3220b6c562f2497f9122594f270ba2ab.json"}}, {"family": "Bliddal", "given": "Mette", "initials": "M"}, {"family": "Potteg\u00e5rd", "given": "Anton", "initials": "A", "orcid": "0000-0001-9314-5679", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1daf4d9300f94bf6916f968437b52a80.json"}}], "type": "journal article", "published": "2021-08-00", "journal": {"title": "Acta Psychiatr Scand", "issn": "1600-0447", "volume": "144", "issue": "2", "pages": "100-112", "issn-l": null}, "abstract": "Hypnotic use in children and adolescents is controversial.\n\nTo describe the use of hypnotic drugs (melatonin, z-drugs, and sedating antihistamines) among 5- to 24-year-old Scandinavians during 2012 to 2018.\n\nAggregate-level data were obtained from public data sources in Sweden, Norway, and Denmark. We calculated annual prevalence (users/1000 inhabitants) stratified by age group, sex, and country. Quantity of use (Defined Daily Dose (DDD)/user/day) was estimated for Norway and Denmark.\n\nMelatonin was the most commonly used hypnotic, and its use increased markedly from 2012 to 2018, particularly among females and 15- to 24-year-old individuals. Sweden had the highest increase in use (6.5 to 25/1000) compared with Norway (10-20/1000) and Denmark (5.7-12/1000). The annual prevalence of sedating antihistamine use was also highest in Sweden, reaching 13/1000 in 2018 in comparison to 7.5/1000 in Norway and 2.5/1000 in Denmark. Z-drug use decreased in all countries toward 2018, dropping to 3.5/1000 in Sweden, 4.4/1000 in Norway, and 1.7/1000 in Denmark. The quantity of hypnotic use in Norway and Denmark was 0.8-1.0 DDD/user/day for melatonin in 2018, as compared to 0.1-0.3 for z-drugs and antihistamines.\n\nThe use of melatonin and sedating antihistamines increased among young Scandinavians during 2012-2018, and the increase was twice as high in Sweden compared with Norway and Denmark. In addition, Sweden had the highest use of sedating antihistamines. The Scandinavian variation of hypnotic use could reflect differences in frequency of sleep problems between populations or variation of healthcare access or clinical practice between countries.", "doi": "10.1111/acps.13329", "pmid": "34021908", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T09:59:52.674Z", "modified": "2026-09-23T10:37:29.122Z"}, {"entity": "publication", "iuid": "50017f7dc1534a7bb3cb353746fa8c43", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/50017f7dc1534a7bb3cb353746fa8c43.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/50017f7dc1534a7bb3cb353746fa8c43"}}, "title": "Trends in antidepressant use among children and adolescents: a Scandinavian drug utilization study.", "authors": [{"family": "Wesselhoeft", "given": "R", "initials": "R", "orcid": "0000-0001-9700-2739", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/29670ecb185844689260deb334d8ef10.json"}}, {"family": "Jensen", "given": "P B", "initials": "PB"}, {"family": "Talati", "given": "A", "initials": "A"}, {"family": "Reutfors", "given": "J", "initials": "J"}, {"family": "Furu", "given": "K", "initials": "K"}, {"family": "Strandberg-Larsen", "given": "K", "initials": "K"}, {"family": "Damkier", "given": "P", "initials": "P", "orcid": "0000-0003-0591-7187", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3220b6c562f2497f9122594f270ba2ab.json"}}, {"family": "Potteg\u00e5rd", "given": "A", "initials": "A", "orcid": "0000-0001-9314-5679", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1daf4d9300f94bf6916f968437b52a80.json"}}, {"family": "Bliddal", "given": "M", "initials": "M"}], "type": "journal article", "published": "2020-01-00", "journal": {"title": "Acta Psychiatr Scand", "issn": "1600-0447", "volume": "141", "issue": "1", "pages": "34-42", "issn-l": null}, "abstract": "To compare antidepressant utilization in individuals aged 5-19 years from the Scandinavian countries.\n\nA population-based drug utilization study using publicly available data of antidepressant use from Denmark, Norway, and Sweden.\n\nIn the study period from 2007 to 2017, the proportion of antidepressant users increased markedly in Sweden (9.3-18.0/1000) compared to Norway (5.1-7.6/1000) and Denmark (9.3-7.5/1000). In 2017, the cumulated defined daily doses (DDD) of selective serotonin reuptake inhibitors were 5611/1000 inhabitants in Sweden, 2709/1000 in Denmark, and 1848/1000 in Norway. The use of 'other antidepressants' (ATC code N06AX) also increased in Sweden with a higher DDD in 2017 (497/1000) compared to Denmark (225/1000) and Norway (170/1000). The use of tricyclic antidepressants was generally low in 2017 with DDDs ranging between 30-42 per 1000. The proportion of antidepressant users was highest among 15- to 19-year-old individuals. Girls were more likely to receive treatment than boys, and the treated female/male ratios per 1000 were similar in Sweden (2.39), Denmark (2.44), and Norway (2.63).\n\nEven in highly comparable healthcare systems like the Scandinavian countries', variation in antidepressant use is considerable. Swedish children and adolescents have a markedly higher and still increasing use of antidepressants compared to Danish and Norwegian peers.", "doi": "10.1111/acps.13116", "pmid": "31618447", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T08:43:15.599Z", "modified": "2026-09-23T08:43:15.848Z"}]}